Kaposi Sarcoma

This is a type of cancer that causes reddish-purple spots or nodules, usually on the skin, especially on the legs and feet. It's caused by a virus (HHV-8) and can affect people with weakened immune systems, like those with AIDS, or people who have had organ transplants. It can also occur in other groups.

Condition

What people with Kaposi Sarcoma report

Every report comes from a Lived member, sent anonymously.

Have you tried Highly Active Antiretroviral Therapy for Kaposi Sarcoma?

NameHow it went

About Kaposi Sarcoma

What It Is

Kaposi sarcoma (KS) is a cancer that grows from the cells lining blood and lymph vessels. It usually shows up as purple, red or brown patches, raised plaques or lumps on the skin, most often on the legs, feet or face, and sometimes inside the mouth. The spots are made of abnormal cells, small new blood vessels and blood cells, which is why they can look like bruises that never fade. Many lesions cause no pain, but lesions on the legs or groin can block lymph drainage and cause painful swelling, and KS can also grow in lymph nodes, the lungs or the digestive tract, where it is more serious. KS behaves differently from most cancers. Rather than starting in one place and spreading, it often appears in several places at once. Doctors recognize four main types that share the same cause but behave differently. HIV-associated (epidemic) KS is the most common type in the United States. Classic KS affects mainly older adults, more often men, of Mediterranean, Eastern European Jewish or Middle Eastern heritage, and usually grows slowly over many years. Transplant-related KS develops in people taking medicines that suppress the immune system after an organ transplant. Endemic KS occurs in sub-Saharan Africa, where it can be aggressive in children.

Causes & Risk Factors

Every type of KS is caused by infection with human herpesvirus 8 (HHV-8), also called Kaposi sarcoma-associated herpesvirus (KSHV). The virus infects cells lining blood and lymph vessels and pushes them to divide too much and survive longer than they should. It seems to spread mainly through saliva. Fewer than 1 in 10 people in the United States and most of Europe carry it, while in some parts of Africa up to 8 in 10 do. Once someone is infected, the virus stays in the body for life. Infection alone rarely leads to cancer: most people with HHV-8 never develop KS. It develops mainly when the immune system can no longer keep the virus in check. HIV is the largest risk factor. Even in the era of modern HIV treatment, people living with HIV in the United States have a risk of KS roughly 500 times that of the general population, although effective antiretroviral therapy lowers that risk considerably. Medicines that prevent organ rejection raise risk in a similar way, and the gradual weakening of immunity with age likely helps explain classic KS. Men are more likely than women to develop every type, and men who have sex with men have a higher risk regardless of HIV status. There is no vaccine against HHV-8.

How It's Diagnosed

KS is often suspected from how the spots look, but appearance alone cannot confirm it. A biopsy is needed: a small piece of a lesion, usually taken with a punch tool after local numbing, is examined under a microscope by a pathologist. Anyone not recently tested for HIV is offered an HIV test, since the answer changes treatment. The care team then works out how far KS reaches and how well the immune system is working, because both shape the plan. This usually means a full check of the skin and mouth, feeling for enlarged lymph nodes, a stool test for hidden blood and blood counts. For people with HIV, the CD4 count (a measure of the immune cells HIV destroys) is especially important: a count below 200 cells per microliter signals a more weakened immune system and a higher-risk group in the staging system doctors use for HIV-associated KS. A chest X-ray looks for KS in the lungs. CT scans, bronchoscopy (a thin camera passed into the airways) or endoscopy (a camera passed into the stomach or bowel) are used when symptoms or other results point to internal disease. Because classic KS in older adults is usually slow and limited to the skin, the workup for that type is often lighter.

Treatment Options

KS usually cannot be cured outright, because HHV-8 stays in the body, but treatment can often keep it under control for many years. The plan depends on the type of KS, how many lesions there are and where, whether they cause problems, and how well the immune system works. Lesions that cause no trouble, particularly in classic KS, may simply be watched and treated only if they grow or start causing symptoms. Restoring the immune system comes first when that is possible. For HIV-associated KS, antiretroviral therapy (ART, the combination of HIV medicines) is the foundation of treatment: as immunity recovers, lesions often shrink, and for many people ART alone is enough. For transplant-related KS, the transplant team may lower the anti-rejection medicines or switch to a type called an mTOR inhibitor, such as sirolimus, which can help control KS. Either change has to be balanced against the risk of the body rejecting the new organ. A few troublesome skin or mouth lesions can be treated locally with radiation therapy, freezing (cryotherapy), surgical removal, chemotherapy injected directly into the lesion, or a medicine applied to the skin, such as a retinoid (a vitamin A-related drug). Local treatment improves the treated spot but does not stop new lesions elsewhere. Compression stockings often help leg swelling. Widespread skin disease, painful swelling, or KS in the lungs or digestive tract usually calls for chemotherapy given into a vein. Liposomal doxorubicin (Doxil), a chemotherapy drug packaged in tiny fat particles that collect in KS tissue, and paclitaxel are the usual first choices; if one stops working, the other can be tried. In most people chemotherapy shrinks lesions and eases symptoms without clearing KS completely, and it can be paused when the disease is quiet and restarted if it grows. Because chemotherapy also weakens the immune system, doctors weigh tumor control against infection risk, and for people with HIV they check for interactions with HIV medicines. For KS that keeps growing, pomalidomide (Pomalyst), a daily capsule that acts on the immune system, is FDA-approved for adults whose HIV-associated KS progresses despite ART and for adults with KS who do not have HIV. The approval rests on how often tumors shrank in a small study, not yet on proof of longer survival. Pomalidomide can cause severe birth defects, so it is available only through a restricted program with pregnancy testing and contraception rules, and it raises the risk of blood clots, so it is usually taken with aspirin or another blood thinner. Immune checkpoint inhibitors such as pembrolizumab (Keytruda) or nivolumab (Opdivo) are sometimes used off label after other treatments, based on small studies. Clinical trials are another option worth asking about.

What to Expect

The course depends heavily on the type of KS and the state of the immune system. Classic KS typically progresses slowly over 10 years or more, with existing spots enlarging gradually and new ones appearing, and many people need treatment only from time to time. People with classic KS are more likely to develop a second cancer, most often non-Hodgkin lymphoma, which is one reason regular follow-up matters. HIV-associated KS tends to be more active, but when ART restores immune function, lesions often fade and stay under control for years. Transplant-related KS may improve or even go away when immune-suppressing medicines are reduced. In the first months after starting or changing HIV treatment, existing KS can suddenly flare, with lesions becoming swollen or tender and new swelling of the legs, or KS can appear for the first time. This reaction, called immune reconstitution inflammatory syndrome (IRIS), happens as the recovering immune system reacts. HIV treatment is usually continued, and chemotherapy is added if needed. Corticosteroid medicines such as prednisone are generally avoided in this situation because they can make KS dramatically worse. Survival figures give only a broad picture. Among people diagnosed in the United States from 2015 to 2021, those with KS were about 75% as likely as people without it to be alive five years later: about 84% when KS was confined to one area and 50% when it had spread to distant parts of the body. These numbers do not account for the type of KS or how well the immune system works, which matter as much as spread, and outcomes for people diagnosed today may be better. Day to day, living with KS often means managing visible skin changes, leg swelling and treatment schedules alongside HIV or transplant care. Follow-up visits check the skin and mouth, track blood counts and immune markers, and watch for new symptoms, and treatment can be resumed or changed if KS becomes active again.

When to Seek Help

See a clinician about purple, red or brown spots or lumps on the skin or inside the mouth that do not fade like a bruise, particularly if you have HIV, have had an organ transplant or take medicine that suppresses the immune system. People with HIV benefit from regular skin and mouth checks by a clinician experienced in recognizing KS. If you have KS, contact your care team promptly about a new cough or shortness of breath, belly pain or diarrhea, stools that look darker than usual, unusual tiredness that may signal slow blood loss, lesions that grow quickly or become painful or oozing, or new swelling in the legs, especially in the first months after starting or changing HIV treatment. Coughing up blood, passing a large amount of blood or black, tarry stool, or severe difficulty breathing needs emergency care: call 911 or go to an emergency department.

Questions to Ask Your Doctor

  1. 1.Which type of Kaposi sarcoma do I have, and what does that suggest about how it is likely to behave?
  2. 2.Could KS be in my lymph nodes, lungs or digestive tract, and do I need tests to check?
  3. 3.Does my KS need treatment now, or is watching it reasonable, and what would change that decision?
  4. 4.How will we balance treating the KS with protecting my immune system, my HIV treatment or my transplant?
  5. 5.Which changes in my skin, breathing or bowel movements should I report right away, and how do I reach you?

Last reviewed • Oct 2026

Educational content, not medical advice.